GlassScriptPhysician profile
Steven P Lander
NPI 1598375503
$1,211.37
in general payments reported to CMS, 2019-2025
10 companies · $832 in 2025
The $832 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $379 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $393.66 | 2024-2025 | Tremfya, Stelara |
| Mallinckrodt Hospital Products INC. | $150.12 | 2025 | Terlivaz |
| Boston Scientific Corporation | $145.74 | 2025 | Spyglass |
| Janssen Scientific Affairs, LLC | $140.91 | 2024 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $126.87 | 2024 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.42 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.68 | 2025 | Entyvio |
| Celltrion USA INC. | $35.25 | 2025 | Vegzelma |
| Novo Nordisk INC | $32.26 | 2025 | Wegovy |
| Lilly USA, LLC | $15.46 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.